Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA May 26 | 2023Carvykti’s Type II Variation Application Submitted to the EMA; Carvykti’s Submission to the FDA Planned; Could Carvykti be First Approved for ≥2L MM in Europe Ahead of the US?Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 May 23 | 2023Encouraging Preclinical Data from ARI-0003, a New Academic Dual CAR-T for NHL; Can ARI-0003 Repeat the Success of ARI-0001? MiNK Tx Presented Preclinical Data of MiNK-215 in NSCLC; ASCGT 2023 Analysis 3Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics May 23 | 2023No Cell Therapy-Related Updates in May’s CHMP Agenda; Abecma Likely to Be Included in June’s AgendaAccess Free BlastFree
Posted in: Autologous, CAR-T May 22 | 2023SC-DARIC33 Shows Promising Preliminary Clinical Results; 2seventy Bio Reveals Next-Generation AML Program; ASGCT 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T May 19 | 2023Ph1 TSCAN-001 Trial Shows Encouraging Preliminary Results; TScan to Initiate Trial in Solid Tumors in 2023; 8 IND Submissions Expected by YE 2024; Kelonia Presents Promising In Vivo CAR-T Preclinical Results; ASCGT 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, Topics May 19 | 2023Legend to Present Multiple Updates at ASCO and EHA 2023; Legend to Use Raised Funding for Carvykti’s Development; Legend’s Q1 2023 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, Topics May 18 | 2023Why Kite's New Leader Makes Strategic Sense for Gilead; Allogene’s CMO Pursues Other OpportunitiesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist, Topics May 16 | 2023GC012F Results in MM and NHL to Be Presented at ASCO and EHA; New GC012F Trial in SLE; GC007g Demonstrates Remarkable Ph1 IIT Results in ALL; Gracell’s Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR May 15 | 2023Adaptimmune and TCR2 Tx to Discuss Merger at the End of May; Completion of Afami-cel’s rolling BLA Submission Remains on Track; Adaptimmune’s and TCR2 Tx’s Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 May 10 | 2023CB-010 to Be Evaluated in 2L LBCL; CB-011’s Ph1 Trial in MM Initiated; No Updates on Poseida’s Milestones for 2023; Caribou’s and Poseida’s Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist May 10 | 2023Arcellx’s CART-ddBCMA Program to Be Expanded; Precision to Provide Clinical Updates on Azer-cel and PBCAR19B Programs in May 2023; Arcellx’s and Precision’s Q1 2023 Results SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD123, CD22 May 08 | 2023Cellectis to Deprioritize its Multiple Myeloma Program; All Ongoing Trials to Include Sanofi’s Alemtuzumab as Lymphodepleting Agent; Cellectis’s Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 May 05 | 2023ALLO-501’s ALPHA2 Trial Progresses but EXPAND Study Might Experience Difficulties to Enroll; ALLO-316’s AACR Results Highlighted; Allogene Ready for Partnerships to Advance its Programs; Allogene’s Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T May 05 | 2023Abecma’s US Revenue Continues to Increase; DARIC33’s Data to Be Presented at ASGCT 2023; Manufacturing Capacity Ramping Up; 2seventy bio's Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 May 05 | 2023Obe-cel’s BLA Submission on Track for YE 2023; Launch Preparedness Activities Underway; Cardinal Health to Serve as Autolus’s US Commercial Distribution Partner; Autolus's Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 May 04 | 2023The EC Grants Breyanzi Marketing Authorization in 2L LBCLAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 May 03 | 2023JNJ to Invest in CAR-T Therapies for LymphomaAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 May 03 | 2023Thoughts on Breyanzi Positive Results in R/R FL and MCLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 28 | 2023Gilead’s Cell Therapy Revenues Continue to Grow; Arcellx and Tmunity Deals Completed; Yescarta and Tecartus NICE Recommendations in England; Gilead's Q1 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 28 | 2023Abecma and Breyanzi Sales Accelerate; Initiation of CAR-T Program in Immunology; Vector Manufacturing Facility Acquisition; Leadership Transition Plan; BMS’s Q1 2023 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.